Clinical Assessment of Endothelial Dysfunction and Investigationof New Therapies in Cardiovascular Diseases

本文应用反应性充血外周动脉张力测定（RH-PAT）和血浆内皮源性微粒（EMP）检测对临床上怀疑冠心病和心力衰竭患者的血管内皮功能进行了评价。我们发现CD 144-EMP是LVEF降低的心力衰竭患者心血管事件的独立预后因素。我们证实了冠状动脉微血管痉挛性心绞痛患者存在冠状动脉内皮功能障碍，并确定了其独特的临床特征。在LVEF正常的心力衰竭患者中，用RH-PAT试验评估的血管内皮功能是未来心血管事件的重要和独立的因素。我们证明，DPP-IV抑制剂（西格列汀），一种治疗糖尿病的新药，改善血管内皮功能，显着抑制动脉粥样硬化形成的ApoE缺陷小鼠，一种小鼠模型的动脉粥样硬化。

We examined Reactive Hyperemia Peripheral Arterial Tonometry(RH-PAT) test and measurement of plasma levels of Endothelium-derived Microparticles(EMP) in patients suspected with coronary artery disease and heart failure patients inorder to assess vascular endothelial dysfunction clinically. We found CD144-EMP was anindependent prognostic factor for cardiovascular events in patients with heart failurewith reduced LVEF. We demonstrated the presence of coronary endothelial dysfunction andidentified distinctive clinical features in patients with coronary microvascular spasticangina. The vascular endothelial function assessed by RH-PAT test in patients with heartfailure with normal LVEF (HFNEF) was a significant and independent factor of the futurecardiovascular events. We demonstrated that the treatment by DPP-IV inhibitor(Sitagliptin); a new medicine for diabetes, improved the vascular endothelial functionand significantly inhibited atherosclerosis formation in the ApoE deficiency mouse, amouse model of atherosclerosis.